Someone’s mad about drug price hikes. For once, it’s not Bernie Sanders or Hillary Clinton -- it’s the CEO of a big U.S. biotech company.
Regeneron Pharmaceuticals Inc. Chief Executive Officer Leonard Schleifer jumped into the drug pricing debate Thursday at a health-care conference, accusing fellow drug company executives he shared a stage with of raising prices to cover up a lack of innovation.
